Gayle G. Sherman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gayle G. Sherman has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Ashraf H. Coovadia
4 shared publicationsEmma Kalk
From the *Paediatric HIV Diagnostic Syndicate, Wits Health Consortium; †Department of Paediatrics, Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand; ‡National Health Laboratory Service; and §Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
2 shared publicationsJanet C. Patton
Wits Pediatric HIV Clinics, Wits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa
2 shared publicationsRivka R. Lilian
Paediatric HIV Diagnostic Syndicate, Wits Health Consortium, Johannesburg, South Africa
2 shared publicationsTammy M. Meyers
Wits Pediatric HIV Clinics, Wits Health Consortium,1 Departments of Molecular Medicine and Hematology,2 Pediatrics, University of the Witwatersrand,3 National Health Laboratory Service, Johannesburg, South Africa4
2 shared publications- Adrian Puren
National Institute for Communicable Diseases
1 shared publication
Latest Publications
- 1 October 2013
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 32 (10) , 1080-1085
Birth Diagnosis of HIV Infection in Infants to Reduce Infant Mortality and Monitor for Elimination of Mother-to-child Transmission
Background: Early initiation of antiretroviral therapy depends on an early infant diagnosis and is critical to reduce HIV-related infant mortality. We describe the implementation of a routine prevention of mother-to-child transmission program and focus on early infant diagnosis to identify opportunities to improve outcomes. Methods: HIV-exposed infants and their mothers were enrolled in a prospective, observational cohort study at a routine, hospital-based prevention of mother-to-child transmission and HIV treatment service in Johannesburg, South Africa. Infant HIV status was determined by testing samples collected between birth and 6 weeks and searching the national laboratory information system for polymerase chain reaction results of defaulting infants who accessed testing elsewhere. Results: Of 838 enrolled infants, HIV status was determined for 606 (72.3%) by testing at the study site, 85 (10.1%) by accessing test results from other facilities, 19 (2.3%) by testing stored samples and remained unknown in 128 (15.3%) infants. In total, 38 perinatally HIV-infected infants were identified. Thirty (79%) HIV-infected infants accessed 6-week testing and initiated antiretroviral therapy at a median age of 16.0 weeks, but only 14 were in care a median of 68 weeks later and 4 had died. Eight (21%) HIV-infected infants, 2 of whom died, escaped identification by routine testing. Their mothers were younger, more likely to be foreign and accessed less optimal antenatal care. Conclusions: Six-week testing delayed antiretroviral therapy initiation beyond the time of early HIV-related infant mortality and missed one-fifth of perinatally HIV-infected infants. Earlier diagnosis and improved retention in care are required to reduce infant mortality and accurately measure elimination of mother-to-child transmission.
- 1 October 2013
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 32 (10) , 1080-1085
Birth Diagnosis of HIV Infection in Infants to Reduce Infant Mortality and Monitor for Elimination of Mother-to-child Transmission
Background: Early initiation of antiretroviral therapy depends on an early infant diagnosis and is critical to reduce HIV-related infant mortality. We describe the implementation of a routine prevention of mother-to-child transmission program and focus on early infant diagnosis to identify opportunities to improve outcomes. Methods: HIV-exposed infants and their mothers were enrolled in a prospective, observational cohort study at a routine, hospital-based prevention of mother-to-child transmission and HIV treatment service in Johannesburg, South Africa. Infant HIV status was determined by testing samples collected between birth and 6 weeks and searching the national laboratory information system for polymerase chain reaction results of defaulting infants who accessed testing elsewhere. Results: Of 838 enrolled infants, HIV status was determined for 606 (72.3%) by testing at the study site, 85 (10.1%) by accessing test results from other facilities, 19 (2.3%) by testing stored samples and remained unknown in 128 (15.3%) infants. In total, 38 perinatally HIV-infected infants were identified. Thirty (79%) HIV-infected infants accessed 6-week testing and initiated antiretroviral therapy at a median age of 16.0 weeks, but only 14 were in care a median of 68 weeks later and 4 had died. Eight (21%) HIV-infected infants, 2 of whom died, escaped identification by routine testing. Their mothers were younger, more likely to be foreign and accessed less optimal antenatal care. Conclusions: Six-week testing delayed antiretroviral therapy initiation beyond the time of early HIV-related infant mortality and missed one-fifth of perinatally HIV-infected infants. Earlier diagnosis and improved retention in care are required to reduce infant mortality and accurately measure elimination of mother-to-child transmission.
- 1 July 2012
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 50 (7) , 2373-2377
Early Diagnosis of In Utero and Intrapartum HIV Infection in Infants Prior to 6 Weeks of Age
Early initiation of antiretroviral therapy reduces HIV-related infant mortality. The early peak of pediatric HIV-related deaths in South Africa occurs at 3 months of age, coinciding with the earliest age at which treatment is initiated following PCR testing at 6 weeks of age. Earlier diagnosis is necessary to reduce infant mortality. The performances of the Amplicor DNA PCR, COBAS AmpliPrep/COBAS TaqMan (CAP/CTM), and Aptima assays for detecting early HIV infection (acquired in utero and intrapartum) up to 6 weeks of age were compared. Dried blood spots (DBS) were collected at birth and at 2, 4, and 6 weeks from HIV-exposed infants enrolled in an observational cohort study in Johannesburg, South Africa. HIV status was determined at 6 weeks by DNA PCR on whole blood. Serial DBS samples from all HIV-infected infants and two HIV-uninfected, age-matched controls were tested with the 3 assays. Of 710 infants of known HIV status, 38 (5.4%) had in utero (n = 29) or intrapartum (n = 9) infections. By 14 weeks, when treatment should have been initiated, 13 (45%) in utero-infected and 2 (22%) intrapartum-infected infants had died or were lost to follow-up. The CAP/CTM and Aptima assays identified 76.3% of all infants with early HIV infections at birth and by 4 weeks were 96% sensitive. DNA PCR demonstrated lower sensitivities at birth and 4 weeks of 68.4% and 87.5%, respectively. All assays had the lowest sensitivity at 2 weeks of age. CAP/CTM was the only assay with 100% specificity at all ages. Testing at birth versus 6 weeks of age identifies a higher total number of HIV-infected infants, irrespective of the assay.
- 1 July 2012
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 50 (7) , 2373-2377
Early Diagnosis of In Utero and Intrapartum HIV Infection in Infants Prior to 6 Weeks of Age
Early initiation of antiretroviral therapy reduces HIV-related infant mortality. The early peak of pediatric HIV-related deaths in South Africa occurs at 3 months of age, coinciding with the earliest age at which treatment is initiated following PCR testing at 6 weeks of age. Earlier diagnosis is necessary to reduce infant mortality. The performances of the Amplicor DNA PCR, COBAS AmpliPrep/COBAS TaqMan (CAP/CTM), and Aptima assays for detecting early HIV infection (acquired in utero and intrapartum) up to 6 weeks of age were compared. Dried blood spots (DBS) were collected at birth and at 2, 4, and 6 weeks from HIV-exposed infants enrolled in an observational cohort study in Johannesburg, South Africa. HIV status was determined at 6 weeks by DNA PCR on whole blood. Serial DBS samples from all HIV-infected infants and two HIV-uninfected, age-matched controls were tested with the 3 assays. Of 710 infants of known HIV status, 38 (5.4%) had in utero (n = 29) or intrapartum (n = 9) infections. By 14 weeks, when treatment should have been initiated, 13 (45%) in utero-infected and 2 (22%) intrapartum-infected infants had died or were lost to follow-up. The CAP/CTM and Aptima assays identified 76.3% of all infants with early HIV infections at birth and by 4 weeks were 96% sensitive. DNA PCR demonstrated lower sensitivities at birth and 4 weeks of 68.4% and 87.5%, respectively. All assays had the lowest sensitivity at 2 weeks of age. CAP/CTM was the only assay with 100% specificity at all ages. Testing at birth versus 6 weeks of age identifies a higher total number of HIV-infected infants, irrespective of the assay.
- 1 March 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (3) , 267-272
The Performance of 5 Rapid HIV Tests Using Whole Blood in Infants and Children
Rapid tests have the potential to improve the identification of HIV-infected children in resource-limited settings. However, they remain underutilized because of a lack of data on their performance in the field using whole blood specimens. This study aimed to assess the accuracy of rapid tests for detecting HIV exposure, excluding HIV infection in HIV-exposed infants, and diagnosing HIV infection in children older than 18 months of age. Five rapid tests (First Response, Pareekshak, Determine, Smart Check, and Insti) were performed using whole blood from children enrolled in a multisite, cross-sectional study in South Africa. HIV enzyme-linked immunosorbent assay and DNA polymerase chain reaction results defined HIV exposure and infection, respectively, and were the standards used for comparison. Of the 851 children enrolled, 186 (21.9%) were infected with HIV. For detecting HIV exposure, Determine demonstrated the highest sensitivity of 99.3% (95% confidence interval, 98.0-99.8) in early infancy, but sensitivity declined with age as seroreversion occurred. After 8 months of age, all tests except First Response excluded HIV infection in 82% to 100% of HIV-uninfected infants and, in conjunction with a clinical assessment, did not miss any HIV-infected children. Insti was the only test that detected all HIV-infected infants, albeit on the smallest number of samples. The performance of all rapid tests in children older than 18 months of age was similar to that in adults. Determine was the only rapid test that had a high enough sensitivity for detecting HIV exposure in early infancy, but it identified seroreversion later in life than the other tests. Insti warrants further investigation for both indications.
- 1 March 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (3) , 267-272
The Performance of 5 Rapid HIV Tests Using Whole Blood in Infants and Children
Rapid tests have the potential to improve the identification of HIV-infected children in resource-limited settings. However, they remain underutilized because of a lack of data on their performance in the field using whole blood specimens. This study aimed to assess the accuracy of rapid tests for detecting HIV exposure, excluding HIV infection in HIV-exposed infants, and diagnosing HIV infection in children older than 18 months of age. Five rapid tests (First Response, Pareekshak, Determine, Smart Check, and Insti) were performed using whole blood from children enrolled in a multisite, cross-sectional study in South Africa. HIV enzyme-linked immunosorbent assay and DNA polymerase chain reaction results defined HIV exposure and infection, respectively, and were the standards used for comparison. Of the 851 children enrolled, 186 (21.9%) were infected with HIV. For detecting HIV exposure, Determine demonstrated the highest sensitivity of 99.3% (95% confidence interval, 98.0-99.8) in early infancy, but sensitivity declined with age as seroreversion occurred. After 8 months of age, all tests except First Response excluded HIV infection in 82% to 100% of HIV-uninfected infants and, in conjunction with a clinical assessment, did not miss any HIV-infected children. Insti was the only test that detected all HIV-infected infants, albeit on the smallest number of samples. The performance of all rapid tests in children older than 18 months of age was similar to that in adults. Determine was the only rapid test that had a high enough sensitivity for detecting HIV exposure in early infancy, but it identified seroreversion later in life than the other tests. Insti warrants further investigation for both indications.
- 1 February 2010
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (2) , 169-172
ORAL FLUID TESTS FOR SCREENING OF HUMAN IMMUNODEFICIENCY VIRUS-EXPOSED INFANTS
In high human immunodeficiency virus (HIV) prevalence settings, routine screening of infants attending immunization visits could improve identification of HIV-exposed infants to receive an early diagnosis and appropriate interventions. This first assessment of 2 rapid oral fluid HIV tests in early infancy demonstrates a sensitivity of <90% for detection of HIV-exposure resulting in failure to detect at least 1 in 10 HIV-infected infants.
- 1 February 2010
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (2) , 169-172
ORAL FLUID TESTS FOR SCREENING OF HUMAN IMMUNODEFICIENCY VIRUS-EXPOSED INFANTS
In high human immunodeficiency virus (HIV) prevalence settings, routine screening of infants attending immunization visits could improve identification of HIV-exposed infants to receive an early diagnosis and appropriate interventions. This first assessment of 2 rapid oral fluid HIV tests in early infancy demonstrates a sensitivity of <90% for detection of HIV-exposure resulting in failure to detect at least 1 in 10 HIV-infected infants.
- 1 February 2008
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (2) , 388-391
Evaluation of the Ultrasensitive Human Immunodeficiency Virus Type 1 (HIV-1) p24 Antigen Assay Performed on Dried Blood Spots for Diagnosis of HIV-1 Infection in Infants
The diagnostic accuracy of the modified p24 antigen assay performed on pediatric dried blood spots was evaluated. Samples analyzed within 6 weeks of collection yielded no false-positive results (specificity, 100%) and few false-negative results (sensitivity, 96.5% to 98.3%). Laboratory services with limited resources should assess this option for routine infant diagnosis.
- 1 February 2008
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (2) , 388-391
Evaluation of the Ultrasensitive Human Immunodeficiency Virus Type 1 (HIV-1) p24 Antigen Assay Performed on Dried Blood Spots for Diagnosis of HIV-1 Infection in Infants
The diagnostic accuracy of the modified p24 antigen assay performed on pediatric dried blood spots was evaluated. Samples analyzed within 6 weeks of collection yielded no false-positive results (specificity, 100%) and few false-negative results (sensitivity, 96.5% to 98.3%). Laboratory services with limited resources should assess this option for routine infant diagnosis.
- 1 December 2007
- Published by Elsevier in Journal of Virological Methods
- Vol. 146 (1-2) , 397-400
Low risk of contamination with automated and manual excision of dried blood spots for HIV DNA PCR testing in the routine laboratory
- 1 December 2007
- Published by Elsevier in Journal of Virological Methods
- Vol. 146 (1-2) , 397-400
Low risk of contamination with automated and manual excision of dried blood spots for HIV DNA PCR testing in the routine laboratory
- 1 February 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (2) , 201-203
Evaluation of Dried Whole Blood Spots Obtained by Heel or Finger Stick as an Alternative to Venous Blood for Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Vertically Exposed Infants in the Routine Diagnostic Laboratory
The diagnostic accuracy of the Roche Amplicor human immunodeficiency virus type 1 DNA PCR assay (version 1.5) on DNA extracted from pediatric heel prick dried blood spots using Roche MagNA Pure nucleic acid purification technology was evaluated. The methodologies transfer successfully from the labor-intensive research laboratory to the high-throughput automated routine laboratory.
- 1 February 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (2) , 201-203
Evaluation of Dried Whole Blood Spots Obtained by Heel or Finger Stick as an Alternative to Venous Blood for Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Vertically Exposed Infants in the Routine Diagnostic Laboratory
The diagnostic accuracy of the Roche Amplicor human immunodeficiency virus type 1 DNA PCR assay (version 1.5) on DNA extracted from pediatric heel prick dried blood spots using Roche MagNA Pure nucleic acid purification technology was evaluated. The methodologies transfer successfully from the labor-intensive research laboratory to the high-throughput automated routine laboratory.
- 1 November 2005
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 24 (11) , 993-997
Polymerase Chain Reaction for Diagnosis of Human Immunodeficiency Virus Infection in Infancy in Low Resource Settings
Diagnosis of human immunodeficiency virus (HIV) is essential for accessing treatment. Current HIV diagnostic protocols for infants require adaptation and validation before they can be implemented in the developing world. The timing and type of HIV assays will be dictated by country-specific circumstances and experience from similar settings. The performance of an HIV-1 DNA polymerase chain reaction (PCR) test, and in particular a single test at 6 weeks of age, in diagnosing HIV subtype C infection acquired in utero or peripartum was assessed. A retrospective review of 1825 Amplicor HIV-1 DNA PCR version 1.5 tests performed between 2000 and 2004 in 2 laboratories in Johannesburg, South Africa on 769 effectively non-breast-fed infants from 3 clinically well characterized cohorts was undertaken. The HIV status of each infant was used as the standard against which the HIV PCR results were compared. The overall sensitivity and specificity of the HIV PCR test were 99.3 and 99.5% respectively. A single test was 98.8% sensitive and 99.4% specific in the 627 infants tested at 6 weeks of age (58 HIV-infected and 569 HIV-uninfected). Repeat testing of all positive HIV PCR tests minimized false positive results. In resource-poor settings where HIV PCR testing in an environment of good laboratory practice is feasible, a single 6-week HIV DNA PCR test can increase identification of HIV-infected children substantially from current levels. Further operational research on how best to implement and monitor such a diagnostic protocol in specific local settings, especially in breast-fed infants, is necessary.
- 1 November 2005
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 24 (11) , 993-997
Polymerase Chain Reaction for Diagnosis of Human Immunodeficiency Virus Infection in Infancy in Low Resource Settings
Diagnosis of human immunodeficiency virus (HIV) is essential for accessing treatment. Current HIV diagnostic protocols for infants require adaptation and validation before they can be implemented in the developing world. The timing and type of HIV assays will be dictated by country-specific circumstances and experience from similar settings. The performance of an HIV-1 DNA polymerase chain reaction (PCR) test, and in particular a single test at 6 weeks of age, in diagnosing HIV subtype C infection acquired in utero or peripartum was assessed. A retrospective review of 1825 Amplicor HIV-1 DNA PCR version 1.5 tests performed between 2000 and 2004 in 2 laboratories in Johannesburg, South Africa on 769 effectively non-breast-fed infants from 3 clinically well characterized cohorts was undertaken. The HIV status of each infant was used as the standard against which the HIV PCR results were compared. The overall sensitivity and specificity of the HIV PCR test were 99.3 and 99.5% respectively. A single test was 98.8% sensitive and 99.4% specific in the 627 infants tested at 6 weeks of age (58 HIV-infected and 569 HIV-uninfected). Repeat testing of all positive HIV PCR tests minimized false positive results. In resource-poor settings where HIV PCR testing in an environment of good laboratory practice is feasible, a single 6-week HIV DNA PCR test can increase identification of HIV-infected children substantially from current levels. Further operational research on how best to implement and monitor such a diagnostic protocol in specific local settings, especially in breast-fed infants, is necessary.
- 26 October 2005
- Published by Wiley in Tropical Medicine & International Health
- Vol. 10 (11) , 1108-1113
Is early HIV testing of infants in poorly resourced prevention of mother to child transmission programmes unaffordable?
Summary: Objectives Paediatric HIV infection is predominantly vertically transmitted and 90% of the global burden is carried by Sub Saharan Africa. Diagnosis of HIV infection is important to ensure access to appropriate healthcare. Prevention of mother to child transmission (PMTCT) programmes in low resource settings fail to identify HIV‐infected children because of high lost to follow‐up rates by 12 months of age when HIV testing is performed. The cost of diagnosing HIV infection earlier in infancy was measured.Methods A prospective, longitudinal, descriptive study was conducted in a PMTCT clinic in Johannesburg, South Africa over an 18‐month period. From a total of 300 HIV exposed infants enrolled in an infant diagnostic study, a convenience sample of 30 was enrolled in a costing sub‐study. Patient and provider costs incurred in establishing the HIV status of an exposed infant were documented to determine the societal and provider cost of performing HIV testing at 6 weeks and 12 months of age.Results The average societal cost of an earlier diagnosis of HIV is R158 less per patient than current practice as determined from 123 (82%) questionnaires. On average, early diagnosis would cost the provider R8 more per patient. PMTCT clinic attendance figures predict that earlier testing would increase the number of infants diagnosed by almost threefold.Conclusions A marginal additional investment by government to access an earlier HIV diagnosis for infants could triple the efficacy of PMTCT programmes in identifying HIV‐infected children for medical management and improved quality and quantity of life. Early diagnosis offers societal benefits that extend beyond economic savings.
- 26 October 2005
- Published by Wiley in Tropical Medicine & International Health
- Vol. 10 (11) , 1108-1113
Is early HIV testing of infants in poorly resourced prevention of mother to child transmission programmes unaffordable?
Summary: Objectives Paediatric HIV infection is predominantly vertically transmitted and 90% of the global burden is carried by Sub Saharan Africa. Diagnosis of HIV infection is important to ensure access to appropriate healthcare. Prevention of mother to child transmission (PMTCT) programmes in low resource settings fail to identify HIV‐infected children because of high lost to follow‐up rates by 12 months of age when HIV testing is performed. The cost of diagnosing HIV infection earlier in infancy was measured.Methods A prospective, longitudinal, descriptive study was conducted in a PMTCT clinic in Johannesburg, South Africa over an 18‐month period. From a total of 300 HIV exposed infants enrolled in an infant diagnostic study, a convenience sample of 30 was enrolled in a costing sub‐study. Patient and provider costs incurred in establishing the HIV status of an exposed infant were documented to determine the societal and provider cost of performing HIV testing at 6 weeks and 12 months of age.Results The average societal cost of an earlier diagnosis of HIV is R158 less per patient than current practice as determined from 123 (82%) questionnaires. On average, early diagnosis would cost the provider R8 more per patient. PMTCT clinic attendance figures predict that earlier testing would increase the number of infants diagnosed by almost threefold.Conclusions A marginal additional investment by government to access an earlier HIV diagnosis for infants could triple the efficacy of PMTCT programmes in identifying HIV‐infected children for medical management and improved quality and quantity of life. Early diagnosis offers societal benefits that extend beyond economic savings.
- 15 April 2005
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 38 (5) , 615-617
Dried Blood Spots Improve Access to HIV Diagnosis and Care for Infants in Low-Resource Settings
Effective health care delivery to the majority of perinatally exposed infants worldwide, including those enrolled in prevention of mother-to-child transmission programs, is hampered by lack of access to an HIV diagnosis in infancy. Dried blood spot collection from young infants for centralized HIV polymerase chain reaction (PCR) testing is attainable in low-resource settings, provided PCR methodology suitable for routine laboratory service is available. The accuracy of the Roche Amplicor HIV-1 DNA test version 1.5 (Branchburg, NJ) performed on dried blood spots collected prospectively on ordinary Whatman filter paper from a cohort of 300 6-week-old infants born to HIV-infected women in Johannesburg, South Africa, was assessed. Anonymous analysis of the blood spots using a unique DNA extraction procedure was performed in a routine diagnostic laboratory and the results compared with HIV DNA and RNA PCR liquid blood tests at age 6 weeks, and the HIV status of the infant. Dried blood spots were available for 288 infants (96%) of whom 25 (8.7%) were HIV infected. The Roche Amplicor assay yielded a sensitivity of 100% and a specificity of 99.6%. HIV DNA PCR tests on dried blood spots have the potential to improve health care delivery to HIV-affected children in low-resource settings right now.
- 15 April 2005
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 38 (5) , 615-617
Dried Blood Spots Improve Access to HIV Diagnosis and Care for Infants in Low-Resource Settings
Effective health care delivery to the majority of perinatally exposed infants worldwide, including those enrolled in prevention of mother-to-child transmission programs, is hampered by lack of access to an HIV diagnosis in infancy. Dried blood spot collection from young infants for centralized HIV polymerase chain reaction (PCR) testing is attainable in low-resource settings, provided PCR methodology suitable for routine laboratory service is available. The accuracy of the Roche Amplicor HIV-1 DNA test version 1.5 (Branchburg, NJ) performed on dried blood spots collected prospectively on ordinary Whatman filter paper from a cohort of 300 6-week-old infants born to HIV-infected women in Johannesburg, South Africa, was assessed. Anonymous analysis of the blood spots using a unique DNA extraction procedure was performed in a routine diagnostic laboratory and the results compared with HIV DNA and RNA PCR liquid blood tests at age 6 weeks, and the HIV status of the infant. Dried blood spots were available for 288 infants (96%) of whom 25 (8.7%) were HIV infected. The Roche Amplicor assay yielded a sensitivity of 100% and a specificity of 99.6%. HIV DNA PCR tests on dried blood spots have the potential to improve health care delivery to HIV-affected children in low-resource settings right now.